Literature DB >> 22223715

Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey.

Ron Pisters1, Robby Nieuwlaat, Martin H Prins, Jean-Yves Le Heuzey, Aldo P Maggioni, A John Camm, Harry J G M Crijns.   

Abstract

AIMS: In atrial fibrillation (AF) cardioversion is the cornerstone of the rhythm management strategy despite the lack of contemporary data on acute and long-term success. We aim to describe present-day cardioversion of AF and identify characteristics associated with immediate and long-term outcome. METHODS AND
RESULTS: Based on the 5333 AF patients enrolled in the multi-centre prospective Euro Heart Survey on AF we selected the 1801 patients undergoing cardioversion at enrolment. Sinus rhythm (SR) was restored in 630 of 712 (88%), 458 of 643 (71%), and 333 of 446 (75%) (P< 0.001) of the electrical (ECV), intravenous (ivCCV), and oral (oCCV) chemical cardioversions, respectively, at the cost of few (4.2%) major complications. In multivariate analysis, absence of chronic obstructive pulmonary disease (COPD) (P< 0.001), presence of paroxysmal AF (PAF) (P= 0.013), and use of biphasic waveform (P= 0.018) were predictors of successful ECV. For ivCCV PAF (P< 0.001), absence of valvular heart disease (P= 0.004), and heart failure (P= 0.009), the presence of hypertension (P= 0.018) and coronary artery disease (P= 0.007) were predictive. Success of oCCV was driven by PAF (P< 0.001) and a smaller left atrial dimension (P= 0.001). At 1-year follow-up 893 of 1271 (70%) patients were in SR. Multivariate analysis revealed PAF (P< 0.001), shorter total AF history (P< 0.001), continuous use of Class Ic drugs or amiodarone during follow-up (P< 0.001), absence of COPD (P= 0.003), younger age (P= 0.004), and smaller left atrial dimension (P= 0.005) as independent predictors of SR at 1-year follow-up.
CONCLUSIONS: Contemporary cardioversion of AF is routinely successfully and safely performed with a high proportion of patients in SR at 1-year follow-up.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223715     DOI: 10.1093/europace/eur406

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  33 in total

1.  Reverse atrial remodeling in patients who maintain sinus rhythm after electrical cardioversion: evidence derived from the measurement of total atrial conduction time assessed by PA-TDI interval.

Authors:  Patrick Müller; Fabian Schiedat; Johannes-Wolfgang Dietrich; Dong-In Shin; Kaffer Kara; Andreas Mügge; Thomas Deneke
Journal:  J Echocardiogr       Date:  2014-09-06

Review 2.  Outcome of Patients Discharged after their First Detected Episode of Atrial Fibrillation.

Authors:  Sophie Gomes Md; Laure Champ-Rigot Md; Anthony Foucault Md; Pellissier Md Arnaud; Alain Lebon Md; Patrice Scanu Md; Paul Milliez Md PhD
Journal:  J Atr Fibrillation       Date:  2012-04-14

3.  Optimal timing for cardioversion in patients with atrial fibrillation.

Authors:  Tapio Hellman; Tuomas Kiviniemi; Ilpo Nuotio; Fausto Biancari; Tuija Vasankari; Juha Hartikainen; Mika Lehto; K E Airaksinen
Journal:  Clin Cardiol       Date:  2018-07-23       Impact factor: 2.882

Review 4.  A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation.

Authors:  Veronika Ecker; Charles Knoery; Gordon Rushworth; Ian Rudd; Astrid Ortner; David Begley; Stephen J Leslie
Journal:  Clin Cardiol       Date:  2018-06-07       Impact factor: 2.882

5.  Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion.

Authors:  Babar Parvez; M Benjamin Shoemaker; Raafia Muhammad; Rachael Richardson; Lan Jiang; Marcia A Blair; Dan M Roden; Dawood Darbar
Journal:  Heart Rhythm       Date:  2013-02-19       Impact factor: 6.343

6.  [Therapeutic management of non-valvular atrial fibrillation. Update 2013].

Authors:  K Bode; P Sommer; A Bollmann; G Hindricks
Journal:  Herz       Date:  2013-11       Impact factor: 1.443

Review 7.  Vernakalant for the conversion of atrial fibrillation: the new kid on the block?

Authors:  Diego Conde; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-04-16       Impact factor: 1.468

8.  Is delayed cardioversion the better approach in recent-onset atrial fibrillation? Yes.

Authors:  Giovanni Luca Botto; Giovanni Tortora
Journal:  Intern Emerg Med       Date:  2019-12-13       Impact factor: 3.397

Review 9.  Diagnosis and Therapy of Atrial Fibrillation: The Past, The Present and The Future.

Authors:  Denise M S van Marion; Eva A H Lanters; Marit Wiersma; Maurits A Allessie; Bianca B J J M Brundel; Natasja M S de Groot
Journal:  J Atr Fibrillation       Date:  2015-08-31

Review 10.  Cardioversion in Non-Valvular Atrial Fibrillation.

Authors:  Hermann H Klein; Hans-Joachim Trappe
Journal:  Dtsch Arztebl Int       Date:  2015-12-11       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.